Skip to main content

belinostat

Generic: BELINOSTAT·Brand: BELEODAQ

belinostat: 4 clinical trials tracked.

belinostat evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about belinostat, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (4)

Phase 1 Investigation of Belinostat-Based Combinations in Relapsed/Refractory T-Cell Lymphoma

NCT07691450Registry updated 2026-07-09·Phase 1
Not yet recruiting

Primary endpoint: Occurrence of dose-limiting toxicities (DLT) (Arm A)

Interventionalopen40 targetStarted 2027-01Completion 2029-111 site · United StatesCity of Hope Medical Center

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048Registry updated 2026-09-25·Phase 3·CRVS
Recruiting

Primary endpoint: Progression-free survival

InterventionalRandomizedopen150 targetStarted 2024-10Completion 2028-1237 sites · Australia, Canada, United StatesCorvus Pharmaceuticals, Inc.

A Phase II Study of Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

NCT05170334Registry updated 2026-04-06·Phase 2
Active, not recruiting

Primary endpoint: Overall Response Rate

Interventionalopen7 targetStarted 2021-12Completion 2028-011 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE)

NCT04315233Registry updated 2026-09-04·Phase 1
Terminated

Primary endpoint: Rate of Dose Limiting Toxicity (DLT)

Interventionalopen12 enrolledStarted 2021-05Completion 2025-092 sites · United StatesUniversity of Utah